The accelerated approval of a generic drug in the US for HIV prevention shows that it is possible to shorten the path between pharmaceutical innovation and public health. But it also exposes the contradictions of a system capable of developing extraordinary technologies without ensuring that they reach those who need them most. On November 2, 2026, the Indian pharmaceutical company Dr. Reddy's Laboratories announced that it had received provisional approval from the US regula

Ou: a cadeia que nasceu de uma sentença Since August 4th, ANVISA (Brazilian Health Regulatory Agency) has been receiving requests for Special Authorization from companies interested in cultivating Cannabis sativa in Brazil for medicinal purposes. This date marks the operational start of a new production chain, but news reports still primarily treat the issue as another step in the regulation of cannabis. The most interesting aspect lies elsewhere: the timeline for medicinal c

In the first half of 2026, pharmaceutical and artificial intelligence companies announced fourteen major deals totaling at least US$23.6 billion in potential value, according to a survey by analyst Oliver Sprague Kelly. The prevailing interpretation was that the pharmaceutical industry is betting heavily on radical innovation . I spent a good part of my twenty-five years in the industry in environments where such agreements are discussed and approved, and those who have lived